

Psychopharmacology UPDATE

Revolutionary Psychopharmacology: Innovative Therapies for Unmet Psychiatric Needs

TOPICS

- Substance Abuse Treatment
- Rapid-acting Antidepressants
- Novel Agents for Depression and Schizophrenia
- Tardive Dyskinesia
- Prevention and Treatment of Neurodegeneration in Psychotic and Mood Disorders
- How Hallucinogens Can Be Used as Treatments



SYMPOSIUM DIRECTOR

Henry A. Nasrallah, MD

PROFESSOR AND CHAIRMAN

THE SYDNEY W. SOUERS ENDOWED CHAIR AND PROFESSOR

DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL NEUROSCIENCE

SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE, ST. LOUIS, MISSOURI

FACULTY

Mark S. Gold, MD

Chairman
Scientific Advisory Boards
RiverMend Health
Professor
17th University of Florida Alumni Association
Distinguished Professor
Donald R. Dizney Eminent Scholar
Chairman & Emeritus Eminent Scholar
Atlanta, Georgia

Edward C. Lauterbach, MD

Professor Emeritus
Mercer University School of Medicine
Macon, Georgia

Jonathan M. Meyer, MD

Assistant Clinical Professor of Psychiatry
University of California, San Diego
Associate Clinical Professor of Psychiatry
Loma Linda University School of Medicine
Medical Director, Mental Health Intensive Case Management
VA San Diego Medical Center
San Diego, California

Charles L. Raison, MD

Mary Sue and Mike Shannon Chair for Healthy Minds,
Children & Families
Professor
Human Development and Family Studies
School of Human Ecology
Professor
Department of Psychiatry
School of Medicine and Public Health
University of Wisconsin-Madison
Madison, Wisconsin

Gerard Sanacora, PhD, MD

Professor of Psychiatry
Director
Yale Depression Research Program
Yale School of Medicine
New Haven, Connecticut

EARN UP TO
7 AMA PRA
CATEGORY 1
CREDITS™



**SATURDAY
OCTOBER 28, 2017**

**KINGSGATE MARRIOTT
CONFERENCE HOTEL
AT THE UNIVERSITY
OF CINCINNATI**

ENDORSED BY:

Current
PSYCHIATRY

For more information and to register go to:
www.PsychPharmUpdate.org

ABOUT OUR DIRECTOR AND FACULTY

Dear Colleague,

On behalf of the University of Cincinnati and *CURRENT PSYCHIATRY*, it is my pleasure to invite you to attend our 16th Annual Psychopharmacology Update.

At this full-day course, nationally renowned faculty will cover Revolutionary Psychopharmacology: Innovative Therapies for Unmet Psychiatric Needs including substance abuse treatment, rapid-acting antidepressants, novel agents for depression and schizophrenia, tardive dyskinesia, prevention and treatment of neurodegeneration.

This well-established, one-day CME symposium offers an outstanding opportunity for education and networking with minimal disruption to your busy schedule. You will get in-depth analysis from our expert faculty and ample time to query them on topics that will help keep your practice ahead of the curve.

I hope you can come join us in Cincinnati for this informative symposium.

Sincerely,



Henry A. Nasrallah, MD
SYMPOSIUM DIRECTOR



Henry A. Nasrallah, MD

Dr. Henry A. Nasrallah is professor and chair of the Department of Psychiatry at Saint Louis University, and holds the Sydney W. Souers Endowed Chair. He is a widely recognized neuropsychiatrist, educator, and researcher. Dr. Nasrallah's research focuses on the neurobiology and psychopharmacology of schizophrenia and related psychoses. He has published 380 scientific articles, 440 abstracts, as well as 11 books. He is Editor-In-Chief of two journals (*Schizophrenia Research* and *CURRENT PSYCHIATRY*) and is the co-founder of the Schizophrenia International Research Society (SIRS). He has twice received the NAMI Exemplary Psychiatrist Award and was chosen as the U.S.A. Teacher of the Year by the *Psychiatric Times*. He has received more than 90 research grants and is listed in all editions of the book "Best Doctors in America."



Mark S. Gold, MD

Dr. Gold is the Donald D. Eminent Scholar, Distinguished Professor and Chair of Psychiatry at the University of Florida College of Medicine and Chairman of Scientific Advisory boards for RiverMend Health. Dr. Gold has developed translational research models, which have led to new treatments for addiction and also conceptualized novel hypotheses, which yielding new approaches to treating patients.



Edward C. Lauterbach, MD

Dr. Lauterbach received his MD from Wake Forest University and psychiatry residency training from Washington University School of Medicine. He subsequently completed a neurology fellowship in movement disorders and neurodegenerative disease and is ABPN board certified. He is currently Professor Emeritus of Psychiatry and Neurology at Mercer University School of Medicine. His interests have been in psychopharmacology (especially pharmacodynamics and mechanisms of action), neuropsychiatry, and neurodegenerative diseases. His publications have focused on psychopharmacology, pharmacodynamics, and psychiatric conditions in the neurological patient. He has given over 100 invited medical lectures.



Jonathan M. Meyer, MD

Dr. Meyer is Assistant Clinical Professor of Psychiatry at University of California, San Diego, Associate Clinical Professor of Psychiatry at Loma Linda University School of

Medicine, and Medical Director of the Mental Health Intensive Case Management program at the VA San Diego Healthcare System. Dr. Meyer has performed extensive research on the metabolic effects of antipsychotics, and the impact of antipsychotic medications on glucose-insulin homeostasis. Dr. Meyer has published numerous articles and book chapters on various aspects of antipsychotic psychopharmacology.



Charles L. Raison, MD

Dr. Raison serves as the founding Director of the Center for Compassion Studies in the College of Social and Behavioral Sciences at the University of Arizona and is on the Scientific Advisory Board of the Usona Institute. Dr. Raison is internationally recognized for his studies examining novel mechanisms involved in the development and treatment of major depression and other stress-related emotional and physical conditions, as well as for his work examining the physical and behavioral effects of compassion training. Dr. Raison has received a NARSAD Independent Investigator Award and has received the Raymond Pearl Memorial Award from the Human Biology Association "in recognition of his contributions to our understanding of evolutionary biocultural origins of mental health and illness."



Gerard Sanacora, PhD, MD

Dr. Sanacora is Associate Professor and the Director of the Yale Depression Research Program. Dr. Sanacora's work is concentrated largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders. Much of his recent research has focused on identifying the contributions of the amino acid neurotransmitter systems (GABA and Glutamate) to the neurobiology of mood disorders and the mechanism of antidepressant action. His clinical laboratory employs novel magnetic resonance spectroscopy methodologies and pharmacological challenge paradigms to identify abnormalities in the function of the amino acid neurotransmitter systems in individuals suffering from mood and anxiety disorders. In addition, he is involved in several early phase clinical trials designed to test the clinical efficacy of newly developed therapeutic agents.



AGENDA Subject to change. Check PsychPharmUpdate.org for updates.

8:40 am – 9:30 am	Current and Future Parenteral Treatments for Addictions MARK S. GOLD, MD
9:30 am – 10:20 am	Intravenous and Intranasal Rapid-Acting Antidepressants: Part 1 GERARD SANACORA, PHD, MD
10:20 am – 10:45 am	Break/Exhibits
10:45 am – 11:35 pm	Intravenous and Intranasal Rapid-Acting Antidepressants: Part 2 GERARD SANACORA, PHD, MD
11:35 pm – 12:25 pm	Heat Therapy for Depression CHARLES L. RAISON, MD
12:25 pm – 1:40 pm	Lunch Symposium
1:40 pm – 1:55 pm	Dessert Break/Exhibits
1:55 pm – 2:45pm	FDA-Approved Treatment for Tardive Dyskinesia, Finally! JONATHAN M. MEYER, MD
2:45 pm – 3:35 pm	How Hallucinogens Can Be Used as Treatments CHARLES L. RAISON, MD
3:35 pm – 4:25 pm	What's New in Schizophrenia? HENRY A. NASRALLAH, MD
4:25 pm – 4:40 pm	Break
4:40 pm – 5:30 pm	Innovative Strategies to Prevent / Treat Neurodegeneration in Psychotic and Mood Disorders EDWARD C. LAUTERBACH, MD
5:30 pm – 5:45 pm	Q&A Panel

ABOUT OUR VENUE

**Kingsgate Marriott
Conference Hotel**
151 Goodman Avenue
Cincinnati, OH 45219
TEL: 513-487-3800
FAX: 513-487-3810

The Kingsgate Marriott Conference Hotel at the University of Cincinnati is the premier University of Cincinnati hotel. We have arranged for discount room rates of \$134 per night for participants of the Psychopharmacology Update. The cut-off date for the discount rate is October 6, 2017. We suggest you make your arrangements as soon as possible, as our room block will sell out.

**To make your reservations,
please call 888-720-1299
and be sure to mention the
Psychopharmacology Update.**

REGISTRATION PRICING

	Until Aug. 28 2017	Aug. 29 to Sept. 25, 2017	After Sept. 25, 2017
Physicians	\$175	\$225	\$325
OPPA members	\$150	\$200	\$325
Psychologists, Social Workers/ Allied Health	\$150	\$170	\$270
Residents/ Fellows	\$65	\$65	\$65

REGISTRATION FORM (PLEASE PRINT)

FIRST NAME _____		LAST NAME _____	
DEGREE: ☐ MD ☐ DO ☐ NP/PA ☐ PHARM ☐ RN ☐ PHD			
☐ RESIDENT ☐ OTHER, PLEASE SPECIFY _____			
AFFILIATION _____			
TYPE OF PRACTICE: ☐ OFFICE ☐ HOSPITAL ☐ OTHER _____			
ADDRESS _____			
CITY/STATE/ZIP _____			
E-MAIL (for registration confirmation and CME certificate) _____			
PHONE _____		FAX _____	
PAYMENT INFORMATION: CREDIT CARD: ☐ AMEX ☐ MC ☐ VISA ☐ CHECK ENCLOSED (MADE PAYABLE TO PSYCHOPHARMACOLOGY UPDATE)			
CARD NUMBER _____		EXP. DATE _____	
CARDHOLDER SIGNATURE _____		DATE _____	

WAYS TO REGISTER

ONLINE: PsychPharmUpdate.org
BY FAX: (201) 822-6114
BY MAIL: Jennifer Meade
c/o Global Academy for
Medical Education
7 Century Drive, Suite 301
Parsippany, NJ 07054

Cancellation Policy: A refund less a \$50 administrative fee as follows: You may cancel your registration using our online registration system prior to September 19, 2017. After these dates no refunds will be granted. After the refund date, you have two options: you can transfer your registration to another party using our online registration system, or receive a credit in the amount you paid less a \$50 administrative fee to be applied to your registration for next year's conference. Refunds will not be issued to no-shows. Global Academy for Medical Education is not responsible for nonrefundable, nontransferable airline tickets or hotel accommodations purchased for attendance at this course. The registration fee covers attendance to the scientific meeting, continental breakfasts, coffee breaks, lunches when provided, and exhibits

Register online at PsychPharmUpdate.org

Psychopharmacology UPDATE

Register by August 28
Save \$150

Join us for this interactive,
live symposium

Revolutionary Psychopharmacology: Innovative Therapies for Unmet Psychiatric Needs

SATURDAY, OCTOBER 28, 2017
CINCINNATI, OH



EARN UP TO
7 AMA PRA
CATEGORY 1
CREDITS™

Jointly provided by the University of Cincinnati
College of Medicine Department of Psychiatry
and Global Academy for Medical Education

Psychopharmacology Update
7 Century Drive, Suite 301
Parsippany, NJ 07054

Endorsed by: **Current**
PSYCHIATRY

PsychPharmUpdate.org

SYMPOSIUM DIRECTOR



Henry A. Nasrallah, MD
Saint Louis University
School of Medicine

FACULTY

Mark S. Gold, MD
RiverMend Health

Edward C. Lauterbach, MD
Mercer University School of Medicine

Jonathan M. Meyer, MD
University of California
Loma Linda University School of
Medicine
VA San Diego Medical Center

Henry A. Nasrallah, MD
Saint Louis University
School of Medicine

Charles L. Raison, MD
University of Wisconsin-Madison

Gerard Sanacora, PhD, MD
Yale School of Medicine

WHO SHOULD PARTICIPATE?

This activity is designed for child and general psychiatrists, adolescent psychiatrists, geriatric psychiatrists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals interested in treating patients with psychiatric disorders to remission with measurement-based care.

PROGRAM GLOBAL OBJECTIVES

At the conclusion of this CME symposium, those in attendance should be able to:

- Explain the options for managing the positive, negative, and cognitive symptoms of schizophrenia
- Explain how hyperthermia therapy may relieve depression previously resistant to pharmacotherapy
- Identify the differences among the antipsychotic medications in their neuroprotective properties as well as safety profiles
- Discuss the emerging science of neuroplasticity and treatments on the horizon that may preserve or reverse brain function
- Review the data on the efficacy and safety of long-acting injectable medication for the treatment of alcohol and opiate addiction
- Describe how hallucinogens can be used as treatments
- Implement evidence based treatments for TD, including innovative treatment

TOPICS

- Substance Abuse Treatment
- Rapid-acting Antidepressants
- Novel Agents for Depression and Schizophrenia
- Tardive Dyskinesia
- Prevention and Treatment of Neurodegeneration
- How Hallucinogens Can Be Used as Treatments

ACCREDITATION

PHYSICIAN ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education, Inc.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

The University of Cincinnati designates this Live Activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS CREDIT DESIGNATION

The American Academy of Physician Assistants (AAPA) accepts Category 1 CME approval from organizations accredited by the ACCME to grant Category 1 hours toward the PRA.

This activity is endorsed by CURRENT PSYCHIATRY.